Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Thierry André, M.D., Corrado Boni, M.D., Lamia Mounedji-Boudiaf, M.D., Matilde Navarro, M.D., Josep Tabernero, M.D., Tamas Hickish, M.D., Clare Topham, M.D., Marta Zaninelli, M.D., Philip Clingan, M.D., John Bridgewater, M.D., Isabelle Tabah-Fisch, M.D., Aimery de Gramont, M.D., for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators
Background The standard adjuvant treatment of colon canceris fluorouracil plus leucovorin (FL). Oxaliplatin improves theefficacy of this combination in patients with metastatic colorectalcancer. We evaluated the efficacy of treatment with FL plusoxaliplatin in the postoperative adjuvant setting.
Methods We randomly assigned 2246 patients who had undergonecurative resection for stage II or III colon cancer to receiveFL alone or with oxaliplatin for six months. The primary endpoint was disease-free survival.
Results A total of 1123 patients were randomly assigned toeach group. After a median follow-up of 37.9 months, 237 patientsin the group given FL plus oxaliplatin had had a cancer-relatedevent, as compared with 293 patients in the FL group (21.1 percentvs. 26.1 percent; hazard ratio for recurrence, 0.77; P=0.002).The rate of disease-free survival at three years was 78.2 percent(95 percent confidence interval, 75.6 to 80.7) in the groupgiven FL plus oxaliplatin and 72.9 percent (95 percent confidenceinterval, 70.2 to 75.7) in the FL group (P=0.002 by the stratifiedlog-rank test). In the group given FL plus oxaliplatin, theincidence of febrile neutropenia was 1.8 percent, the incidenceof gastrointestinal adverse effects was low, and the incidenceof grade 3 sensory neuropathy was 12.4 percent during treatment,decreasing to 1.1 percent at one year of follow-up. Six patientsin each group died during treatment (death rate, 0.5 percent).
Conclusions Adding oxaliplatin to a regimen of fluorouraciland leucovorin improves the adjuvant treatment of colon cancer.
Source Information
From Hôpital Tenon, Paris (T.A.); GERCOR Oncology Multidisciplinary Group, Paris (T.A., A.G.); Arcispedale Santa Maria Nuova, Reggio Emilia, Italy (C.B.); Sanofi-Synthelabo, Paris (L.M.-B., I.T.-F.); Hospital Duran i Reynals, l'Hospitalet de Llobregat, Llobregat, Spain (M.N.); Vall d'Hebron University Hospital, Barcelona, Spain (J.T.); Dorset Cancer Centre, Royal Bournemouth and Poole Hospitals, Bournemouth, United Kingdom (T.H.); Royal Surrey County Hospital, Guildford, Surrey, United Kingdom (C.T.); Ospedale Borgotrento, Verona, Italy (M.Z.); Southern Medical Day Care Centre, Wollongong, Australia (P.C.); North Middlesex Hospital, London (J.B.); and Hôpital Saint-Antoine, Paris (A.G.).
Address reprint requests to Dr. de Gramont at Hôpital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris 75012, France, or at aimery.de-gramont{at}sat.ap-hop-paris.fr.
Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Colangelo, L. H., Lopa, S. H., Petrelli, N. J., Goldberg, R. M., Atkins, J. N., Seay, T. E., Fehrenbacher, L., O'Reilly, S., Chu, L., Azar, C. A., Wolmark, N.
(2009). Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. JCO
27: 3385-3390
[Abstract][Full Text]
Andre, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., de Gramont, A.
(2009). Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. JCO
27: 3109-3116
[Abstract][Full Text]
Van Cutsem, E., Labianca, R., Bodoky, G., Barone, C., Aranda, E., Nordlinger, B., Topham, C., Tabernero, J., Andre, T., Sobrero, A. F., Mini, E., Greil, R., Di Costanzo, F., Collette, L., Cisar, L., Zhang, X., Khayat, D., Bokemeyer, C., Roth, A. D., Cunningham, D.
(2009). Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. JCO
27: 3117-3125
[Abstract][Full Text]
O'Connell, M. J.
(2009). Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In. JCO
27: 3082-3084
[Full Text]
Kemeny, N., Capanu, M., D'Angelica, M., Jarnagin, W., Haviland, D., Dematteo, R., Fong, Y.
(2009). Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol
20: 1236-1241
[Abstract][Full Text]
Okoshi, K., Nagayama, S., Furu, M., Mori, Y., Yoshizawa, A., Toguchida, J., Sakai, Y.
(2009). A Case Report of Pathologically Complete Response of a Huge Rectal Cancer after Systemic Chemotherapy with mFOLFOX6. Jpn J Clin Oncol
0: hyp045v1-hyp045
[Abstract][Full Text]
Nordlinger, B., Van Cutsem, E., Gruenberger, T., Glimelius, B., Poston, G., Rougier, P., Sobrero, A., Ychou, M., on behalf of the European Colorectal Metastases Tr,
(2009). Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol
20: 985-992
[Abstract][Full Text]
Van Cutsem, E., Oliveira, J., On behalf of the ESMO Guidelines Working Group,
(2009). Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol
20: iv49-iv50
[Full Text]
Ychou, M., Raoul, J.-L., Douillard, J.-Y., Gourgou-Bourgade, S., Bugat, R., Mineur, L., Viret, F., Becouarn, Y., Bouche, O., Gamelin, E., Ducreux, M., Conroy, T., Seitz, J.-F., Bedenne, L., Kramar, A.
(2009). A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol
20: 674-680
[Abstract][Full Text]
Park, S. B., Goldstein, D., Lin, C. S.-Y., Krishnan, A. V., Friedlander, M. L., Kiernan, M. C.
(2009). Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. JCO
27: 1243-1249
[Abstract][Full Text]
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., Seitz, J. F., Francini, G., Haller, D., Yothers, G., Goldberg, R., de Gramont, A.
(2009). Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials. JCO
27: 872-877
[Abstract][Full Text]
Waldman, S. A., Hyslop, T., Schulz, S., Barkun, A., Nielsen, K., Haaf, J., Bonaccorso, C., Li, Y., Weinberg, D. S.
(2009). Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. JAMA
301: 745-752
[Abstract][Full Text]
BIR, A. S., FORA, A. A., LEVEA, C., FAKIH, M. G.
(2009). Spontaneous Regression of Colorectal Cancer Metastatic to Retroperitoneal Lymph Nodes. Anticancer Res
29: 465-468
[Abstract][Full Text]
Papamichael, D., Audisio, R., Horiot, J.-C., Glimelius, B., Sastre, J., Mitry, E., Van Cutsem, E., Gosney, M., Kohne, C.-H., Aapro, M.
(2009). Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol
20: 5-16
[Abstract][Full Text]
Martinez-Cardus, A., Martinez-Balibrea, E., Bandres, E., Malumbres, R., Gines, A., Manzano, J. L., Taron, M., Garcia-Foncillas, J., Abad, A.
(2009). Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Molecular Cancer Therapeutics
8: 194-202
[Abstract][Full Text]
Takagawa, R., Fujii, S., Ohta, M., Nagano, Y., Kunisaki, C., Yamagishi, S., Osada, S., Ichikawa, Y., Shimada, H.
(2008). Preoperative Serum Carcinoembryonic Antigen Level as a Predictive Factor of Recurrence After Curative Resection of Colorectal Cancer. Ann. Surg. Oncol.
15: 3433-3439
[Abstract][Full Text]
Bilchik, A. J.
(2008). Perioperative Carcinoembryonic Antigen Measurements to Predict Curability After Liver Resection for Colorectal Metastases--Invited Critique. Arch Surg
143: 1158-1159
[Full Text]
Yokoo, S., Masuda, S., Yonezawa, A., Terada, T., Katsura, T., Inui, K.-i.
(2008). Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer. Drug Metab. Dispos.
36: 2299-2306
[Abstract][Full Text]
Mitry, E., Fields, A. L.A., Bleiberg, H., Labianca, R., Portier, G., Tu, D., Nitti, D., Torri, V., Elias, D., O'Callaghan, C., Langer, B., Martignoni, G., Bouche, O., Lazorthes, F., Van Cutsem, E., Bedenne, L., Moore, M. J., Rougier, P.
(2008). Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials. JCO
26: 4906-4911
[Abstract][Full Text]
Grothey, A.
(2008). Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res
17: 529-535
[Abstract]
Lurje, G., Zhang, W., Schultheis, A. M., Yang, D., Groshen, S., Hendifar, A. E., Husain, H., Gordon, M. A., Nagashima, F., Chang, H. M., Lenz, H.-J.
(2008). Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol
19: 1734-1741
[Abstract][Full Text]
Geoerger, B., Doz, F., Gentet, J.-C., Mayer, M., Landman-Parker, J., Pichon, F., Chastagner, P., Rubie, H., Frappaz, D., Le Bouil, A., Gupta, S., Vassal, G.
(2008). Phase I Study of Weekly Oxaliplatin in Relapsed or Refractory Pediatric Solid Malignancies. JCO
26: 4394-4400
[Abstract][Full Text]
Tuffaha, H. W, Treish, I. M, Zaru, L.
(2008). The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting. J Oncol Pharm Pract
14: 131-138
[Abstract]
Vasilevskaya, I. A., Selvakumaran, M., O'Dwyer, P. J.
(2008). Disruption of Signaling through SEK1 and MKK7 Yields Differential Responses in Hypoxic Colon Cancer Cells Treated with Oxaliplatin. Mol. Pharmacol.
74: 246-254
[Abstract][Full Text]
Qvortrup, C., Yilmaz, M., Ogreid, D., Berglund, A., Balteskard, L., Ploen, J., Fokstuen, T., Starkhammar, H., Sorbye, H., Tveit, K., Pfeiffer, P.
(2008). Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. Ann Oncol
19: 1154-1159
[Abstract][Full Text]
Schwartz, R. N.
(2008). Management of early and advanced colorectal cancer: Therapeutic issues. Am J Health Syst Pharm
65: S8-S14
[Abstract][Full Text]
Keating, N. L., Landrum, M. B., Klabunde, C. N., Fletcher, R. H., Rogers, S. O., Doucette, W. R., Tisnado, D., Clauser, S., Kahn, K. L.
(2008). Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?. JCO
26: 2532-2537
[Abstract][Full Text]
Glimelius, B., Sorbye, H., Balteskard, L., Bystrom, P., Pfeiffer, P., Tveit, K., Heikkila, R., Keldsen, N., Albertsson, M., Starkhammar, H., Garmo, H., Berglund, A.
(2008). A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Ann Oncol
19: 909-914
[Abstract][Full Text]
Di Paolo, A., Lencioni, M., Amatori, F., Di Donato, S., Bocci, G., Orlandini, C., Lastella, M., Federici, F., Iannopollo, M., Falcone, A., Ricci, S., Del Tacca, M., Danesi, R.
(2008). 5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer. Clin. Cancer Res.
14: 2749-2755
[Abstract][Full Text]
Greene, F. L., Sobin, L. H.
(2008). The Staging of Cancer: A Retrospective and Prospective Appraisal. CA Cancer J Clin
58: 180-190
[Abstract][Full Text]
Goel, S.
(2008). Reporting of Subset Analysis: Where Do We Draw the Line?. JCO
26: 2062-2063
[Full Text]
Ng, R., Pond, G. R., Tang, P. A., MacIntosh, P. W., Siu, L. L., Chen, E. X.
(2008). Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol
19: 481-486
[Abstract][Full Text]
Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S. H., Brennscheidt, U., Feyereislova, A., Delord, J.-P
(2008). A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Ann Oncol
19: 332-339
[Abstract][Full Text]
Berglund, A., Cedermark, B., Glimelius, B.
(2008). Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?. Ann Oncol
19: 400-402
[Full Text]
Ezumi, K., Yamamoto, H., Murata, K., Higashiyama, M., Damdinsuren, B., Nakamura, Y., Kyo, N., Okami, J., Ngan, C. Y., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., Nojima, H., Monden, M.
(2008). Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer. Clin. Cancer Res.
14: 677-684
[Abstract][Full Text]
Weiser, M. R., Landmann, R. G., Kattan, M. W., Gonen, M., Shia, J., Chou, J., Paty, P. B., Guillem, J. G., Temple, L. K., Schrag, D., Saltz, L. B., Wong, W. D.
(2008). Individualized Prediction of Colon Cancer Recurrence Using a Nomogram. JCO
26: 380-385
[Abstract][Full Text]
Tsimberidou, A. M., Wierda, W. G., Plunkett, W., Kurzrock, R., O'Brien, S., Wen, S., Ferrajoli, A., Ravandi-Kashani, F., Garcia-Manero, G., Estrov, Z., Kipps, T. J., Brown, J. R., Fiorentino, A., Lerner, S., Kantarjian, H. M., Keating, M. J.
(2008). Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. JCO
26: 196-203
[Abstract][Full Text]
Lim, S. J., Feig, B. W., Wang, H., Hunt, K. K., Rodriguez-Bigas, M. A., Skibber, J. M., Ellis, V., Cleary, K., Chang, G. J.
(2008). Sentinel Lymph Node Evaluation Does Not Improve Staging Accuracy in Colon Cancer. Ann. Surg. Oncol.
15: 46-51
[Abstract][Full Text]
Zlobec, I., Baker, K., Minoo, P., Jass, J. R., Terracciano, L., Lugli, A.
(2008). Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression. Clin. Cancer Res.
14: 143-148
[Abstract][Full Text]
Khorana, A. A., Liebman, H. A., White, R. H., Wun, T., Lyman, G. H.
(2008). The Risk of Venous Thromboembolism in Patients with Cancer. Am Soc Clin Oncol Ed Book
2008: 240-248
[Abstract][Full Text]
Grothey, A.
(2007). Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clin. Cancer Res.
13: 6909s-6912s
[Abstract][Full Text]
Benson, A. B. III
(2007). New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease. Clin. Cancer Res.
13: 6913s-6920s
[Abstract][Full Text]
Aschele, C., Lonardi, S.
(2007). Multidisciplinary treatment of rectal cancer: medical oncology.. Ann Oncol
18: 1908-1915
[Full Text]
Sargent, D. J., Patiyil, S., Yothers, G., Haller, D. G., Gray, R., Benedetti, J., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., Grothey, A., O'Connell, M., Catalano, P. J., Kerr, D., Green, E., Wieand, H. S., Goldberg, R. M., de Gramont, A.
(2007). End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group. JCO
25: 4569-4574
[Abstract][Full Text]
Grossman, S. R., Lyle, S., Resnick, M. B., Sabo, E., Lis, R. T., Rosinha, E., Liu, Q., Hsieh, C.-C., Bhat, G., Frackelton, A. R. Jr., Hafer, L. J.
(2007). p66 Shc Tumor Levels Show a Strong Prognostic Correlation with Disease Outcome in Stage IIA Colon Cancer. Clin. Cancer Res.
13: 5798-5804
[Abstract][Full Text]
Diaz-Rubio, E., Tabernero, J., Gomez-Espana, A., Massuti, B., Sastre, J., Chaves, M., Abad, A., Carrato, A., Queralt, B., Reina, J. J., Maurel, J., Gonzalez-Flores, E., Aparicio, J., Rivera, F., Losa, F., Aranda, E.
(2007). Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. JCO
25: 4224-4230
[Abstract][Full Text]
Mayer, R. J.
(2007). Should Capecitabine Replace Infusional Fluorouracil and Leucovorin When Combined With Oxaliplatin in Metastatic Colorectal Cancer?. JCO
25: 4165-4167
[Full Text]
Sezeur, A., Chatelet, F.P., Cywiner, Ch., de Labriolle-Vaylet, Cl., Chastang, C., Billotey, Cl., Malafosse, M., Gallot, D., Betton, P., Montravers, F., Carvajal-Gonzalez, S., Askienazy, S., Talbot, J.N., Rain, J.D., Milhaud, G., Saumon, G., Barbet, J., Gruaz-Guyon, A.
(2007). Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging. Clin. Cancer Res.
13: 5592s-5597s
[Abstract][Full Text]
Meropol, N. J.
(2007). A Renewed Call for Equipoise. JCO
25: 3392-3394
[Full Text]
Saltz, L. B., Niedzwiecki, D., Hollis, D., Goldberg, R. M., Hantel, A., Thomas, J. P., Fields, A. L.A., Mayer, R. J.
(2007). Irinotecan Fluorouracil Plus Leucovorin Is Not Superior to Fluorouracil Plus Leucovorin Alone As Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803. JCO
25: 3456-3461
[Abstract][Full Text]
Iddings, D. M., Koda, E. A., Grewal, S. S., Parker, R., Saha, S., Bilchik, A.
(2007). Association of Angiogenesis Markers With Lymph Node Metastasis in Early Colorectal Cancer. Arch Surg
142: 738-745
[Abstract][Full Text]
Punt, C. J. A., Buyse, M., Kohne, C.-H., Hohenberger, P., Labianca, R., Schmoll, H. J., Pahlman, L., Sobrero, A., Douillard, J.-Y.
(2007). Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials. JNCI J Natl Cancer Inst
99: 998-1003
[Abstract][Full Text]
Liang, J.-T., Huang, K.-C., Lai, H.-S., Lee, P.-H., Sun, C.-T.
(2007). Oncologic Results of Laparoscopic D3 Lymphadenectomy for Male Sigmoid and Upper Rectal Cancer with Clinically Positive Lymph Nodes. Ann. Surg. Oncol.
14: 1980-1990
[Abstract][Full Text]
Kemeny, N.
(2007). Presurgical Chemotherapy in Patients Being Considered for Liver Resection. The Oncologist
12: 825-839
[Abstract][Full Text]
Morris, E. J. A., Maughan, N. J., Forman, D., Quirke, P.
(2007). Identifying Stage III Colorectal Cancer Patients: The Influence of the Patient, Surgeon, and Pathologist. JCO
25: 2573-2579
[Abstract][Full Text]
Wilson, T. R., McLaughlin, K. M., McEwan, M., Sakai, H., Rogers, K. M.A., Redmond, K. M., Johnston, P. G., Longley, D. B.
(2007). c-FLIP: A Key Regulator of Colorectal Cancer Cell Death. Cancer Res.
67: 5754-5762
[Abstract][Full Text]
Fuse, N., Doi, T., Ohtsu, A., Takeuchi, S., Kojima, T., Taku, K., Tahara, M., Muto, M., Asaka, M., Yoshida, S.
(2007). Feasibility of Oxaliplatin and Infusional Fluorouracil/Leucovorin (FOLFOX4) for Japanese Patients with Unresectable Metastatic Colorectal Cancer. Jpn J Clin Oncol
37: 434-439
[Abstract][Full Text]
Spunt, S. L., Freeman, B. B. III, Billups, C. A., McPherson, V., Khan, R. B., Pratt, C. B., Stewart, C. F.
(2007). Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors. JCO
25: 2274-2280
[Abstract][Full Text]
O'Dwyer, P. J., Eckhardt, S. G., Haller, D. G., Tepper, J., Ahnen, D., Hamilton, S., Benson, A. B. III, Rothenberg, M., Petrelli, N., Lenz, H.-J., Diasio, R., DuBois, R., Sargent, D., Sloan, J., Johnson, C. D., Comis, R. L., O'Connell, M. J.
(2007). Priorities in Colorectal Cancer Research: Recommendations From the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. JCO
25: 2313-2321
[Abstract][Full Text]
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., Zapas, J. L., Goodwin, J. W., Fehrenbacher, L., Ramanathan, R. K., Conley, B. A., Flynn, P. J., Soori, G., Colman, L. K., Levine, E. A., Lanier, K. S., Wolmark, N.
(2007). Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07. JCO
25: 2198-2204
[Abstract][Full Text]
Land, S. R., Kopec, J. A., Cecchini, R. S., Ganz, P. A., Wieand, H. S., Colangelo, L. H., Murphy, K., Kuebler, J. P., Seay, T. E., Needles, B. M., Bearden, J. D. III, Colman, L. K., Lanier, K. S., Pajon, E. R. Jr, Cella, D., Smith, R. E., O'Connell, M. J., Costantino, J. P., Wolmark, N.
(2007). Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07. JCO
25: 2205-2211
[Abstract][Full Text]
Benson, A. B. III
(2007). The Hope for Today--The Promise for Tomorrow: Will Oncologists Meet the Challenge?. JCO
25: 2156-2158
[Full Text]
Ahmad, A., Chen, S. L., Bilchik, A. J.
(2007). Role of Repeated Hepatectomy in the Multimodal Treatment of Hepatic Colorectal Metastases. Arch Surg
142: 526-532
[Abstract][Full Text]
Muss, H. B., Biganzoli, L., Sargent, D. J., Aapro, M.
(2007). Adjuvant Therapy in the Elderly: Making the Right Decision. JCO
25: 1870-1875
[Abstract][Full Text]
Sanoff, H. K., Bleiberg, H., Goldberg, R. M.
(2007). Managing Older Patients With Colorectal Cancer. JCO
25: 1891-1897
[Abstract][Full Text]
Wolpin, B. M., Meyerhardt, J. A., Mamon, H. J., Mayer, R. J.
(2007). Adjuvant Treatment of Colorectal Cancer. CA Cancer J Clin
57: 168-185
[Abstract][Full Text]
Linch, M, Cunningham, D, Mingo, O, Stiles, A, Farquhar-Smith, W.
(2007). Renal tubular acidosis due to oxaliplatin. Ann Oncol
18: 805-806
[Full Text]
Tsujino, T., Seshimo, I., Yamamoto, H., Ngan, C. Y., Ezumi, K., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., Monden, M.
(2007). Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer. Clin. Cancer Res.
13: 2082-2090
[Abstract][Full Text]
de Haas, R. J., Wicherts, D. A., Hobbelink, M. G. G., Rinkes, I. H. M. B., Schipper, M. E. I., van der Zee, J.-A., van Hillegersberg, R.
(2007). Sentinel Lymph Node Mapping in Colon Cancer: Current Status. Ann. Surg. Oncol.
14: 1070-1080
[Abstract][Full Text]
Wang, W.-S., Lin, J.-K., Lin, T.-C., Chen, W.-S., Jiang, J.-K., Wang, H.-S., Chiou, T.-J., Liu, J.-H., Yen, C.-C., Chen, P.-M.
(2007). Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients. The Oncologist
12: 312-319
[Abstract][Full Text]
Gelibter, A. J., Di Segni, S., Zeuli, M., Milella, M., Ferretti, G., Nuzzo, C., Cognetti, F.
(2007). Old Age: Biologic Versus Chronologic. JCO
25: e8-e8
[Full Text]
Schmoll, H.-J., Cartwright, T., Tabernero, J., Nowacki, M. P., Figer, A., Maroun, J., Price, T., Lim, R., Van Cutsem, E., Park, Y.-S., McKendrick, J., Topham, C., Soler-Gonzalez, G., de Braud, F., Hill, M., Sirzen, F., Haller, D. G.
(2007). Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients. JCO
25: 102-109
[Abstract][Full Text]
Rodel, C., Liersch, T., Hermann, R. M., Arnold, D., Reese, T., Hipp, M., Furst, A., Schwella, N., Bieker, M., Hellmich, G., Ewald, H., Haier, J., Lordick, F., Flentje, M., Sulberg, H., Hohenberger, W., Sauer, R.
(2007). Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer. JCO
25: 110-117
[Abstract][Full Text]
Gill, S., Blackstock, A. W., Goldberg, R. M.
(2007). Colorectal Cancer. Mayo Clin Proc.
82: 114-129
[Abstract][Full Text]
Popat, S, Chen, Z, Zhao, D, Pan, H, Hearle, N, Chandler, I, Shao, Y, Aherne, W, Houlston, R.
(2006). A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol
17: 1810-1817
[Abstract][Full Text]
Portier, G., Elias, D., Bouche, O., Rougier, P., Bosset, J.-F., Saric, J., Belghiti, J., Piedbois, P., Guimbaud, R., Nordlinger, B., Bugat, R., Lazorthes, F., Bedenne, L.
(2006). Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial. JCO
24: 4976-4982
[Abstract][Full Text]
Van Cutsem, E., Moiseyenko, V. M., Tjulandin, S., Majlis, A., Constenla, M., Boni, C., Rodrigues, A., Fodor, M., Chao, Y., Voznyi, E., Risse, M.-L., Ajani, J. A.
(2006). Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. JCO
24: 4991-4997
[Abstract][Full Text]
Bartlett, D. L., Berlin, J., Lauwers, G. Y., Messersmith, W. A., Petrelli, N. J., Venook, A. P.
(2006). Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Ann. Surg. Oncol.
13: 1284-1292
[Full Text]
Benson, A. B. III
(2006). New Approaches to the Adjuvant Therapy of Colon Cancer. The Oncologist
11: 973-980
[Abstract][Full Text]
Schmoll, H.-J., Arnold, D.
(2006). Update on Capecitabine in Colorectal Cancer. The Oncologist
11: 1003-1009
[Abstract][Full Text]
Meropol, N. J., Gold, P. J., Diasio, R. B., Andria, M., Dhami, M., Godfrey, T., Kovatich, A. J., Lund, K. A., Mitchell, E., Schwarting, R.
(2006). Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer. JCO
24: 4069-4077
[Abstract][Full Text]
Goldberg, R. M., Tabah-Fisch, I., Bleiberg, H., de Gramont, A., Tournigand, C., Andre, T., Rothenberg, M. L., Green, E., Sargent, D. J.
(2006). Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer. JCO
24: 4085-4091
[Abstract][Full Text]
Faivre, S, Raymond, E
(2006). Management of neuromuscular dose limiting toxicity at the early stage of drug development.. Ann Oncol
17: 1343-1346
[Full Text]
Chen, S. L., Iddings, D. M., Scheri, R. P., Bilchik, A. J.
(2006). Lymphatic Mapping and Sentinel Node Analysis: Current Concepts and Applications. CA Cancer J Clin
56: 292-309
[Abstract][Full Text]
Chau, I, Cunningham, D
(2006). Adjuvant therapy in colon cancer--what, when and how?. Ann Oncol
17: 1347-1359
[Abstract][Full Text]
Monga, D. K., O'Connell, M. J.
(2006). Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions. Ann. Surg. Oncol.
13: 1021-1034
[Abstract][Full Text]
Stipa, F., Chessin, D. B., Shia, J., Paty, P. B., Weiser, M., Temple, L. K. F., Minsky, B. D., Wong, W. D., Guillem, J. G.
(2006). A Pathologic Complete Response of Rectal Cancer to Preoperative Combined-Modality Therapy Results in Improved Oncological Outcome Compared With Those Who Achieve No Downstaging on the Basis of Preoperative Endorectal Ultrasonography. Ann. Surg. Oncol.
13: 1047-1053
[Abstract][Full Text]
Previous
